1. Trial profile
Luc F Van Gaal, Lancet 2005;365:1389

2. Baseline characteristics
Luc F Van Gaal, Lancet 2005;365:1389

3. Change from baseline in bodyweight (A) and waist circumference (B)
Luc F Van Gaal, Lancet 2005;365:1389

4. Changes in metabolic and cardiovascular risk factors in ITT population Part I
Luc F Van Gaal, Lancet 2005;365:1389

5. Changes in metabolic and cardiovascular risk factors in ITT population Part II
Luc F Van Gaal, Lancet 2005;365:1389

6. Changes in metabolic and cardiovascular risk factors in ITT population Part III
Luc F Van Gaal, Lancet 2005;365:1389

7. Changes in selected metabolic and cardiovascular risk factors in patients who completed 1 year follow-up Part I
Luc F Van Gaal, Lancet 2005;365:1389

8. Changes in selected metabolic and cardiovascular risk factors in patients who completed 1 year follow-up Part II
Luc F Van Gaal, Lancet 2005;365:1389

9. Changes in selected metabolic and cardiovascular risk factors in patients who completed 1 year follow-up Part III
Luc F Van Gaal, Lancet 2005;365:1389

10. Proportion of patients who lost 5% and 10% of baseline weight at 1 year
*p<0.001 vs placebo. †p=0.002 vs placebo.
Luc F Van Gaal, Lancet 2005;365:1389

11. Mean percentage change from baseline in HDL-cholesterol (A) and triglycerides (B)
*p<0.001 vs placebo. †p=0.002 vs placebo.
Luc F Van Gaal, Lancet 2005;365:1389

12. Prevalence of the metabolic syndrome in the ITT and completer populations at baseline and after 1 year of treatment
Luc F Van Gaal, Lancet 2005;365:1389

13. Patients reporting adverse events (≥5% in any treatment group)
Luc F Van Gaal, Lancet 2005;365:1389

14. Serious adverse events by system organ class during the double-blind period of the trial
Luc F Van Gaal, Lancet 2005;365:1389

15. Patients reporting adverse events leading to discontinuation
Luc F Van Gaal, Lancet 2005;365:1389

16. Hypothetical model of role of central and peripheral components of endocannabinoid system in regulation of food intake and peripheral metabolism
Luc F Van Gaal, Lancet 2005;365:1389